Inhibitor of DNA methylation

US8207142B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US
• UNIVERSITY OF OREGON · US
• University of Miami School of Medicine · US
• University of Southern California · US
• The University of Miami · US

Inventors

• Eric U. Selker · Eugene, US
• Cindy B. Matsen · Chicago, US
• Peter Jones · Lake Forest, US
• Jonathan Cheng · Alhambra, US
• Sheldon B. Greer · Surfside, US
• Victor E. Marquez · Gaithersburg, US

Key dates

• Filing date: Jul 30, 2002
• Grant date: Jun 26, 2012
• Expiry date: Sep 21, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H21/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Zebularine has hypomethylating activity, and can be used to inhibit, reverse, and/or reduce DNA methylation in vivo and in vitro. Methods are provided for treating methylation-linked conditions through the application of 2-pyrimidinone derivatives, such as Zebularine. Compositions, including pharmaceutical compositions, comprising such derivatives are also provided. Also provided are kits for use in inhibiting DNA methylation, which kits include an amount of a 2-pyrimidinone derivative.